J Neurol Neurosurg Psychiatry 83:473 doi:10.1136/jnnp-2012-302422
  • Editorial commentary

Treating multiple sclerosis with vitamin D

  1. Jeremy Chataway
  1. Correspondence to Dr Jeremy Chataway, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust; Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK; jeremy.chataway{at}
  1. Contributors JC is the Sole contributor.

  • Received 1 February 2012
  • Accepted 2 February 2012
  • Published Online First 12 March 2012

For neurologists, tracking down the cause of multiple sclerosis (MS) has echoes of the search for the elusive Higgs boson. At times close, at times far. Does vitamin D give us a 125 GeV signature? What evidence do we have, and what evidence do we need, for a central role of vitamin D in the pathogenesis of MS? If we divide the current information along traditional observational and interventional lines, then another track may have been visualised. Soilu-Hänninen1 and colleagues asked what would happen if vitamin D (20 000 IU vitamin D3 per week) was added to standard disease modifying …

Visit the full archive of podcasts for JNNP here >>

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article